Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study
Antoine Desîlets(Centre Hospitalier de l’Université de Montréal), Arielle Elkrief(Centre Hospitalier de l’Université de Montréal), Corentin Richard(Centre Georges François Leclerc), Natasha B. Leighl(Princess Margaret Cancer Centre), Rui Kitadai(Tokyo Metropolitan Komagome Hospital), Sally C. M. Lau(University Health Network), Normand Blais(Centre Hospitalier de l’Université de Montréal), Félix Blanc‐Durand(Institut Gustave Roussy), Marie Florescu(Centre Hospitalier de l’Université de Montréal), Chloé Charbonneau(Centre hospitalier universitaire de Québec), Jason Agulnik, Wiam Belkaïd(Université de Montréal), Adrian G. Sacher(Princess Margaret Cancer Centre), Meriem Messaoudene(Centre Hospitalier de l’Université de Montréal), Taiki Hakozaki(Tokyo Metropolitan Komagome Hospital), Houda Bahig(Centre Hospitalier de l’Université de Montréal), Lena Cvetkovic(Centre Hospitalier de l’Université de Montréal), Mustapha Tehfé(Centre Hospitalier de l’Université de Montréal), Scott Owen(McGill University Health Centre), Bertrand Routy(Centre Hospitalier de l’Université de Montréal), Frances A. Shepherd(University Health Network), Nicolas Marcoux(Unknown), Suzanne Kazandjian(Centre Hospitalier de l’Université de Montréal), Geoffrey Liu(Princess Margaret Cancer Centre), Penelope A. Bradbury(University Health Network), Julie Malo(Université de Montréal), Victor Cohen(Jewish General Hospital), Benjamin Shieh, Kevin Jao(Hôpital du Sacré-Cœur de Montréal), Nathalie Daaboul(Hôpital Charles-Le Moyne)
Cited by 78
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k